NCT01317004 - Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Fingolimod

0.5 mg/day oral capsule

DRUG

Standard MS DMT

Interferon beta 1a or interferon beta 1b or Glatiramer Acetate

Trial Locations (17)

12100

Novartis Investigative Site, Cuneo

13900

Novartis Investigative Site, Ponderano

20097

Novartis Investigative Site, San Donato Milanese

20122

Novartis Investigative Site, Milan

20133

Novartis Investigative Site, Milan

22100

Novartis Investigative Site, Como

28100

Novartis Investigative Site, Novara

37045

Novartis Investigative Site, Legnago

41100

Novartis Investigative Site, Modena

50051

Novartis Investigative Site, Castelfiorentino

56126

Novartis Investigative Site, Pisa

60126

Novartis Investigative Site, Ancona

71100

Novartis Investigative Site, Foggia

90129

Novartis Investigative Site, Palermo

90146

Novartis Investigative Site, Palermo

93100

Novartis Investigative Site, Caltanissetta

95122

Novartis Investigative Site, Catania